万众物联
20-99人
公司优势
相关职位
热门城市
20,861+ 岗位更新等你来订阅
一键订阅最新的岗位，每周送达
🎉恭喜你，订阅成功
继续订阅您可以在邮箱中随时取消订阅
公司主要经营兰州504汽水、苏打水、胡萝卜素饮品。
IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. The company has built one of the most comprehensive DNA damage response (DDR) pipelines of novel drug candidates generated through its own research efforts and is expanding into additional novel synthetic lethality targets.
The company's pipeline includes PARP inhibitors (senaparib/IMP4297), Wee1 inhibitors (IMP7068), and other DDR pathway inhibitors. The lead clinical program, PARP inhibitor (senaparib/IMP4297), is in Phase II/III studies for ovarian cancer, prostate cancer, small cell lung cancer, and other indications globally, including China. Early clinical data for senaparib have shown superior tolerability and a wider therapeutic window compared to other PARP inhibitors. A Phase I study of Wee1 inhibitor (IMP7068) is being conducted globally. The Hedgehog pathway inhibitor (IMP5471) has received IND approval from the National Medical Products Administration (NMPA) to initiate clinical studies in China.
Founded and managed by an experienced team from the global pharmaceutical industry, the company has established a complete early-stage research and clinical development organization that has expanded to the United States. The company has received investments from reputable venture capital firms such as Lilly Asia Ventures and strategic investor JunShi Biosciences.
1. **企业概览**：甘肃酒林文华餐饮有限公司，是一家规模较小、员工人数少于50人的民营企业。其主要业务领域集中在餐饮行业。
2. **公司简介**：位于甘肃的酒林文华餐饮有限公司，作为一家民营性质的企业，其运营团队规模适中，员工总数不足50人。该企业专注于餐饮服务，致力于为消费者提供高质量的餐饮体验。
3. **企业详情**：甘肃酒林文华餐饮有限公司，作为一家小型民营企业，拥有员工数低于50人。其主营业务为餐饮服务，旨在通过精心准备的美食和优质的服务，满足顾客对于餐饮的需求。
4. **规模与属性**：甘肃酒林文华餐饮有限公司，作为一家民营性质的企业，其规模相对较小，员工总数限定在50人以下。主要经营方向是餐饮业，致力于提供多样化的餐饮服务。
福建省卓英教育咨询有限公司，公司规模为少于50人，公司类型为民营公司，所属行业为教育/培训/院校。
立生医药专注于呼吸道和眼部疾病领域的生物医药开发、生产和销售。公司目前拥有数条全自动、高效的“吹、灌、封”（BFS）无菌生产线，依托这一技术平台，已有多个产品在中国和美国获得药监局受理，实现了中美市场的双突破。为加速创新成果的转化，公司在2021年底启动了建设亚洲最大BFS技术平台无菌制剂生产基地的项目。该基地占地37亩，总投资7.5亿元人民币，包括研发中试大楼、生产车间和自动化仓库，总建筑面积约57000平方米。基地将引进多条国际先进的BFS生产线和全自动包装线，涵盖吸入雾化剂、滴眼液、软雾制剂、无菌注射制剂等剂型，预计年产能可达15亿支无菌制剂。